252 related articles for article (PubMed ID: 36736928)
21. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
[TBL] [Abstract][Full Text] [Related]
23. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial resistance of Pseudomonas aeruginosa in a cystic fibrosis population after introduction of a novel cephalosporin/β-lactamase inhibitor combination.
Katzenstein TL; Faurholt-Jepsen D; Qvist T; Jensen PØ; Pressler T; Johansen HK; Kolpen M
APMIS; 2023 Aug; 131(8):419-425. PubMed ID: 37294911
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
26. Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018.
Shortridge D; Streit J; Pfaller M; Tulloch M; Chen WT; Castanheira M
J Glob Antimicrob Resist; 2022 Dec; 31():98-103. PubMed ID: 35988706
[TBL] [Abstract][Full Text] [Related]
27. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
28. Comparison of
Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
[TBL] [Abstract][Full Text] [Related]
29. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
Idowu T; Zhanel GG; Schweizer F
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907191
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.
Tuon FF; Cieslinski J; Rodrigues SDS; Serra FB; Paula MD
Braz J Infect Dis; 2020; 24(2):96-103. PubMed ID: 32360070
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against
Sader HS; Carvalhaes CG; Streit JM; Doyle TB; Castanheira M
Microb Drug Resist; 2021 Mar; 27(3):342-349. PubMed ID: 32762605
[TBL] [Abstract][Full Text] [Related]
32. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
33. Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.
Shortridge D; Duncan LR; Pfaller MA; Flamm RK
Int J Antimicrob Agents; 2019 May; 53(5):637-643. PubMed ID: 30716448
[TBL] [Abstract][Full Text] [Related]
34. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Lob SH; Kazmierczak KM; Chen WT; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2022 Jun; 29():527-533. PubMed ID: 34896336
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
38. Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2020 Mar; 20():209-213. PubMed ID: 31351246
[TBL] [Abstract][Full Text] [Related]
39. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Gales A; Castanheira M; Flamm RK
Braz J Infect Dis; 2017; 21(6):627-637. PubMed ID: 28941394
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
